Shanghai Bio-heart Biological Technology Co., Ltd., together with its subsidiaries, engages in the research, development, and commercialization of invasive treatment products in China. The company develops Bioheart, a bioresorbable scaffolds system, which is in registration stage for percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis, a renal denervation system, which is in clinical stage for the treatment of uncontrolled hypertension and resistant hypertension; and DCB, a sirolimus drug coated balloon catheter, which is in clinical stage for the treatment of instent restenosis. It is also involved in local administration and manufacturing services. The company was founded in 2014 and is headquartered in Shanghai, China.
Frequently asked questions
What sector does Shanghai Bio-heart Biological (2185) operate in?
Shanghai Bio-heart Biological belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Shanghai Bio-heart Biological (2185) current stock price?
As of the latest data, Shanghai Bio-heart Biological stock price is HK$1.61, with a previous close of HK$1.60. Shanghai Bio-heart Biological gained HK$0.01 in the last trading session, representing a 0.63% increase.
What is Shanghai Bio-heart Biological (2185) current market capitalization?
Shanghai Bio-heart Biological market cap is approximately 379.48 million.
What is Shanghai Bio-heart Biological (2185) EBITDA?
Shanghai Bio-heart Biological EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -26.89 million.
Does Shanghai Bio-heart Biological (2185) pay dividends?
No. Shanghai Bio-heart Biological does not pay a dividend.
What is Shanghai Bio-heart Biological (2185) beta (volatility) score?
Shanghai Bio-heart Biological has a beta of 0.069, indicating lower volatility than the overall market.
